is a world-leading biopharmaceutical company specialized in the development of marine-based drugs for use in oncology and central nervous system illnesses. * Moreover, the number of patients that showed stabilization or improvement in the MMSE scale was significantly greater in the group treated with Nypta(R) (Tideglusib). * The improvement was more appreciable in the patients who attained the highest dose: they improved in the MMSE and ADAS-cog cognitive scales, the effect being greater than when using cholinesterase inhibitors alone. Those variables are cognitive-behavioral scales for confirming and quantifying a person's mental state. * Patients treated with Nypta(R) (Tideglusib) in addition to an acetylcholinesterase inhibitor as base treatment showed a consistent improvement in four of the five clinical efficacy variables that were assessed: Mini Mental State Examination (MMSE), Alzheimer's Disease Assessment Scale (ADAS-cog), Geriatric Depression State and Global Clinical Assessment. Nevertheless, the following findings are indicative of therapeutic benefit: The drug was also observed to have a positive effect on patients' cognitive performance, though this is not statistically significant due to the small sample size and short treatment period.
Icad madrid trial#
The trial was designed with the primary goal of assessing the safety and tolerability of Nypta(R) (Tideglusib) on these patients. The Phase IIa trial, which was conducted at three centers in Germany based on advice from experts at the European Medicines Agency (EMA), is the first clinical trial of Nypta(R) (Tideglusib) on a group of Alzheimer's patients. In order for these results to be statistically significant, they must be confirmed in a Phase IIb trial in which a larger group of patients will be treated for one year. Teodoro del Ser, Director of Clinical Development at Noscira, gave an oral session in the "Therapeutic Strategies" symposium in which he reported that treatment with Nypta(R) (Tideglusib) for 20 weeks was tolerated and had a positive impact on patients' cognitive performance. MADRID, SPAIN | J| Noscira, the Grupo Zeltia (ZEL.MC) subsidiary specialized in researching and developing drugs for treating neurodegenerative diseases, presented the results of a Phase IIa clinical trial of Nypta(R) (Tideglusib) on Alzheimer's disease (AD) at the International Conference on Alzheimer's Disease (ICAD), held in Honolulu (Hawaii) from July 10-15, 2010.ĭr. In view of the promising results of this trial, Noscira is preparing the next Phase IIb trial on Alzheimer's patients in order to progress with the clinical development of this novel compound.
Dermatology Conferences in Spain 2021/2022/2023 is an indexed listing of upcoming meetings, seminars, congresses, workshops, programs, continuing CME courses, trainings, summits, and weekly, annual or monthly symposiums.ĭermatology Conferences in Spain 2021/2022/2023 lists relevant events for national/international researchers, scientists, scholars, professionals, engineers, exhibitors, sponsors, academic, scientific and university practitioners to attend and present their research activities.ĭermatology Conferences in Spain 2021/2022/2023 will bring speakers from Asia, Africa, North America, South America, Antarctica, Europe, and Australia.ĭermatology conference listings are indexed in scientific databases like Google Scholar, Semantic Scholar, Zenedo, OpenAIRE, EBSCO, BASE, WorldCAT, Sherpa/RoMEO, Compendex, Elsevier, Scopus, Thomson Reuters (Web of Science), RCSI Library, UGC Approved Journals, ACM, CAS, ACTA, CASSI, ISI, SCI, ESCI, SCIE, Springer, Wiley, Taylor Francis, and The Science Citation Index (SCI).- Treatment with Nypta(R) (Tideglusib) (NP-12) was tolerated and produced positive effects on Alzheimer's patients in four of the five efficacy variables examined in the trial.
0 kommentar(er)
